Skin Cancers are the most common of all cancers. Melanomas account for 1% of skin cancers however are a large majority of skin cancer deaths. Melanomas are malignant neoplasms originating from neuroectodermal melanocytes. It is estimated that in the last decade cutaneous melanoma has reached 100,000 new cases per year. Melanomas exhibit strong lymphocytic infiltration that could include partial or complete regressions therefore are one of the best examples of an immunogenic tumor.
Treatment of metastatic melanoma has developed into two major therapeutic advances. Targeted therapies using BRAF and MEK inhibitors towards the BRAF mutation-driven, constitutively-activated MAPK pathway and immunotherapy using immune checkpoint inhibitors. The most common immune checkpoint inhibitors used in the treatment of melanomas include anti-CTLA4 and anti-PD-1 antibodies. Immune checkpoint inhibitors induce cancer-cell-killing CD8-positive T cells by targeting the immune system. The use of immunotherapy has revolutionized the treatment of Melanomas however concerns arise with immune-related adverse events. This Research Topic explores immunotherapy's use for treating melanomas, including the success and drawbacks of the treatment.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advances in immunotherapy in melanomas.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Skin Cancers are the most common of all cancers. Melanomas account for 1% of skin cancers however are a large majority of skin cancer deaths. Melanomas are malignant neoplasms originating from neuroectodermal melanocytes. It is estimated that in the last decade cutaneous melanoma has reached 100,000 new cases per year. Melanomas exhibit strong lymphocytic infiltration that could include partial or complete regressions therefore are one of the best examples of an immunogenic tumor.
Treatment of metastatic melanoma has developed into two major therapeutic advances. Targeted therapies using BRAF and MEK inhibitors towards the BRAF mutation-driven, constitutively-activated MAPK pathway and immunotherapy using immune checkpoint inhibitors. The most common immune checkpoint inhibitors used in the treatment of melanomas include anti-CTLA4 and anti-PD-1 antibodies. Immune checkpoint inhibitors induce cancer-cell-killing CD8-positive T cells by targeting the immune system. The use of immunotherapy has revolutionized the treatment of Melanomas however concerns arise with immune-related adverse events. This Research Topic explores immunotherapy's use for treating melanomas, including the success and drawbacks of the treatment.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advances in immunotherapy in melanomas.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
